Erythrocytes as Drug Carriers in Medicine

Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Hematology
Cover of the book Erythrocytes as Drug Carriers in Medicine by , Springer US
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9781489900449
Publisher: Springer US Publication: June 29, 2013
Imprint: Springer Language: English
Author:
ISBN: 9781489900449
Publisher: Springer US
Publication: June 29, 2013
Imprint: Springer
Language: English

The sixth meeting on the use of resealed annealed red blood cells was held in Irsee, Germany by the International Society for the Use of Resealed Erythrocytes (ISURE) on July 25-28, 1996. Although earlier meetings focused on the technology toward develop­ ment of methods and standardization for efficient, consistent encapsulation, most of the present studies now are directed toward the application use of these carrier blood cells. Basic studies now have been directed toward exploration of commercial applications. In­ deed, clinical trials were initiated to evaluate the dose-response curves employing L­ asparagenase in human patients. Also, studies have shown the use of thrombolytic agent in erythrocyte carriers with the use of human red blood cells to provide a new conceptual ap­ proach in thrombolytic therapy to prevent thrombosis in individuals with higher risk fac­ tors. For example, with the use of carrier red blood cells, the thrombolytic agents will have a greater potential of acting on clot formation without systemic activation and thus lower the risk of hemorrhage, which is always prevalent in the thrombolytic therapy.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

The sixth meeting on the use of resealed annealed red blood cells was held in Irsee, Germany by the International Society for the Use of Resealed Erythrocytes (ISURE) on July 25-28, 1996. Although earlier meetings focused on the technology toward develop­ ment of methods and standardization for efficient, consistent encapsulation, most of the present studies now are directed toward the application use of these carrier blood cells. Basic studies now have been directed toward exploration of commercial applications. In­ deed, clinical trials were initiated to evaluate the dose-response curves employing L­ asparagenase in human patients. Also, studies have shown the use of thrombolytic agent in erythrocyte carriers with the use of human red blood cells to provide a new conceptual ap­ proach in thrombolytic therapy to prevent thrombosis in individuals with higher risk fac­ tors. For example, with the use of carrier red blood cells, the thrombolytic agents will have a greater potential of acting on clot formation without systemic activation and thus lower the risk of hemorrhage, which is always prevalent in the thrombolytic therapy.

More books from Springer US

Cover of the book Capital, Accumulation, and Money by
Cover of the book VLSI Design for Video Coding by
Cover of the book Memory, Consciousness and Temporality by
Cover of the book Expanding Competition in Regulated Industries by
Cover of the book Triple Repeat Diseases of the Nervous Systems by
Cover of the book Teamwork in Neurology by
Cover of the book Workload Characterization for Computer System Design by
Cover of the book Antiphospholipid Syndrome by
Cover of the book Advances in Formal Design Methods for CAD by
Cover of the book Long-Term Management of Patients After Myocardial Infarction by
Cover of the book Handbook of Psychopharmacology by
Cover of the book Growth Factors and the Cardiovascular System by
Cover of the book Psychotherapy for Families after Brain Injury by
Cover of the book Introduction to THz Wave Photonics by
Cover of the book Heart Cell Communication in Health and Disease by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy